ARWR Arrowhead Pharmaceuticals, Inc.

1.52
+0  (3%)
Previous Close 1.48
Open 1.49
Price To book 1.13
Market Cap 113.34M
Shares 74,569,000
Volume 462,918
Short Ratio 13.41
Av. Daily Volume 756,219

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced that development will be discontinued - November 29, 2016.
ARC-AAT
Alpha-1 antitrypsin deficiency (AATD)
Announced that development will be discontinued - November 29, 2016.
ARC-521
Chronic Hepititis B (HBV)
Announced that development will be discontinued - November 29, 2016.
ARC-520 injection in combination with entecavir or tenofovir
Chronic Hepititis B (HBV)

Latest News

  1. Arrowhead Pharmaceuticals Presents ARC-AAT Clinical Data at The International Liver Congress™
  2. Arrowhead Presents ARC-520 and ARC-521 Clinical Data at The International Liver Congress™
  3. ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : April 19, 2017
  4. Arrowhead Pharmaceuticals Announces Presentations at The International Liver Congress™
  5. ETFs with exposure to Arrowhead Pharmaceuticals, Inc. : March 27, 2017
  6. Arrowhead Pharmaceuticals Adopts Stockholder Rights Agreement
  7. Arrowhead Pharmaceuticals, Inc. :ARWR-US: Earnings Analysis: Q1, 2017 By the Numbers : March 21, 2017
  8. SBPH: 2016 Results Sustaining Continued HBV/STING Development
  9. These 5 Stocks Under $10 Could Explode Higher
  10. Edited Transcript of ARWR earnings conference call or presentation 6-Feb-17 9:30pm GMT
  11. Arrowhead Research reports 1Q loss
  12. Arrowhead Reports Fiscal 2017 First Quarter Results
  13. Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on Arrowhead Pharmaceuticals and Jaguar Animal Health
  14. Arrowhead Pharmaceuticals to Webcast Fiscal 2017 First Quarter Results
  15. Robbins Arroyo LLP: Arrowhead Pharmaceuticals, Inc. (ARWR) Misled Shareholders According to a Recently Filed Class Action
  16. IMPORTANT ARWR SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
  17. INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Arrowhead Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm